Safe Cosmetics act


Year in Review: FDA Hot Issues 2017

By: Ronie Schmelz
Counsel at Tucker Ellis LLP

Despite Deregulation in 2017, Cosmetic Companies Remain FDA Focus

President Donald Trump has made deregulation a cornerstone of his administration, demanding that for every new regulation proposed, regulatory agencies identify two regulations for elimination; however, this directive has not impeded regulatory oversight at the U.S. Food and Drug Administration (FDA).  Although the number of FDA Warning Letters sent to cosmetic, skin care, and other personal care companies has decreased significantly under the new administration, these companies still remain a focus for FDA.  While the future is impossible to predict, the following summary of regulatory activity in 2017 provides a good guidepost for the types of claims to avoid so that your company does not become the recipient of an FDA Warning Letter.


As a beauty industry insider and generator of growth for our industry, our mission at COSMOPROF NORTH AMERICA is to provide information to cosmetic companies to allow them to best protect and steward their business interests. There are serious talks brewing in Washington DC over a possible legislative battle taking place where it seems that misinformation is being provided to politicians by radical activist groups which can severely impact the way the business of beauty will be carried out.